Federal Circuit revives REGENXBIO’s suit against Sarepta, reversing a Delaware ruling that found asserted host-cell claims ...
In a significant decision, the Federal Circuit reversed the U.S. International Trade Commission’s (ITC) finding that claims of U.S. Patent No. 10,508,502 (502 Patent) were invalid under 35 U.S.C. § ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results